← Leaderboards
Richard A Himes
Neuroene Therapeutics Inc
$780,724
Attributed
$1,561,448
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $811.5K · FY2018–19$1M$750K$500K$250K$0
'18
'19
Funding mix
By agency
NIH$1,561,448 · 1
By mechanism
R44$1,561,448 · 1
Top collaborators
- Sherine S Chan3 shared
Others in their field
Other Emerging Leaders on “Formulation”
- Matthew Johnson · Duke University$56,071,536
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Jay Evans · University Of Montana$27,950,292
- Kristin Aillon · Midwest Research Institute$24,965,877
Research focus
FormulationIn VivoDrug TargetingEpilepsyFutureIncidenceAdverse EffectsDrug KineticsAcuteEffective TherapyBrain TissueBaseGenerationsHalf-LifeChronicBiological AvailabilityClinical TrialsBiotechnologyCommercializationAntiepileptic AgentsDesignBrainDoseLead
Grant awards (3)
Development of new anti-epilepsy treatments targeting cellular energetics through mitochondrial modulation with optimal pharmacokinetics and toxicity profiles$749,959
R44 · FY2019 · NS
Administrative Supplement to Promote Diversity in Research and Development Small Businesses$61,530
R44 · FY2019 · NS
Development of new anti-epilepsy treatments targeting cellular energetics through mitochondrial modulation with optimal pharmacokinetics and toxicity profiles$749,959
R44 · FY2018 · NS